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 Children with spinal muscular atrophy (SMA) exhibit diminished lean body mass 
and increased fat mass compared to healthy peers; conditions that limit mobility, 
aggravate orthopedic issues, and can potentially affect glucose tolerance and insulin 
sensitivity.  It is unclear whether changes in body composition increase the risk for 
developing metabolic disease such as type II diabetes in this population. The aim of this 
pilot study was to determine whether preadolescents with SMA type II display impaired 
glucose tolerance after glucose loading. 
Data for 6 preadolescents (ages 7-11 years) with SMA type II were collected 
during an oral glucose tolerance test (OGTT).  Baseline lab values were taken after an 
overnight fast to assess hemoglobin A1c, insulin-like growth factor 1 (IGF-1), blood 
glucose, insulin, glucagon, alanine, cortisol, and urinary ketones.  Anthropometric 
measures and dual-energy x-ray absorptiometry (DEXA) scans evaluated body 
composition.  Data from the OGTT indicate that 3 of the 6 patients exhibited impaired 
glucose tolerance with blood glucose levels ˃140 mg/dL.  Based on homeostasis model 
assessment for insulin resistance (HOMA-IR) values, 4 of the 6 patients demonstrated 
insulin resistance and all 6 patients displayed hyperinsulinemia.  Furthermore, DEXA 
analyses on all patients revealed high body fat percentages, with mean values of 71.6% ± 
13.1.  The pilot data provide evidence of glucose and insulin abnormalities in SMA type 




tracking SMA patient risk for metabolic disease.  This knowledge may influence dietary 
management of patients with SMA and provide further insight into glucose metabolism 
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 Spinal muscular atrophy (SMA) is classified as a severe neuromuscular disease 
causing proximal muscle weakness and paralysis by the degeneration of the alpha motor 
neurons in the spinal cord (1).  The rate of incidence is estimated as 1 in 6,000 to 1 in 
10,000 live births, making it the second most frequent autosomal recessive disease.  SMA 
is characterized by mutations in the survival motor neuron 1 (SMN1) gene (1). 
There are four different classifications of the disease (SMA types: I, II, III, and 
IV).  Classifications are determined by age of onset and the degree of motor function 
achieved.  SMA type I is the most common and severe form of the disease, affecting 
about 50% of those diagnosed.  Type II affects 30% of all patients diagnosed (2-4).  
Children with SMA require treatment by an interdisciplinary team including specialists 
from a variety of disciplines: pulmonary, endocrinology, cardiology, neurology, genetics, 
nutrition, physical therapy, social work, and speech and language pathology (3).  
Children with SMA types I and II present with swallowing and gastrointestinal 
complications.  Common problems include bulbar dysfunction, dysphagia, delayed 
gastric emptying, constipation, gastroesophageal reflux, aspiration, and abdominal 
distension/bloating.  Due to swallowing difficulties and poor weight gain, many SMA 
children are diagnosed with failure to thrive during infancy or early childhood and 




Nutritional studies in this patient population have primarily examined nutrient 
intake, body composition, and bone mineral density in SMA type I (5, 6).  Nutrition-
related studies in SMA type II patients are limited; however, two studies have described 
the feeding difficulties and low weight gain commonly found in SMA types II and III (7, 
8).  Dual-energy x-ray absorptiometry (DEXA) analysis has shown that body 
composition comparison of SMA patients to healthy peers results in higher fat mass and 
diminished lean mass, despite the patients being within normal ranges on the BMI growth 
chart (9).   
Glucose metabolism abnormalities may exist in people with SMA.  Patients with 
neuromuscular disease and severely reduced lean body mass demonstrated an increased 
susceptibility to episodes of hypoglycemia during fasting (10, 11).  Bowerman and 
colleagues examined this phenomenon in a SMA mouse model and in pancreatic cells of 
type I SMA patients at autopsy (12).  The SMA mice experienced fasting hyperglycemia, 
hyperglucagonemia, and glucose intolerance after an intraperitoneal glucose tolerance 
test (IPGTT).  Pancreatic samples examined from both the mice and from human SMA 
type I patients revealed that the pancreatic islets exhibited an increase in the number of 
glucagon producing α cells and a progressive loss in insulin producing β cells (12).  A 
more recent study by Bowerman et al., found that the survival of motor neuron (SMN) 
protein facilitates pancreatic development, which when defective or reduced leads to 
dysfunctional glucose metabolism.  Mice with depletions in SMN protein, but without the 
SMA phenotype, experienced increased weight gain, hyperinsulinemia, and an increase 




 Knowledge of glucose metabolism abnormalities and body composition among 
SMA type II children and adolescents during fasting is medically necessary as these 
patients are undergoing more surgical procedures for scoliosis, extension of growth rods, 
contracture release, and gastrostomy placement (14, 15).  Prior to surgery, anesthesia 
protocols often require that patients do not eat anything by mouth for at least 8 hours or 
longer.  Fasting can become problematic and may cause serious side effects associated 
with glucose metabolism abnormalities including hypoglycemia, respiratory 
insufficiency, and a potential fatty acid metabolism disorder (16-18).  Skeletal muscle is 
an important source of gluconeogenic amino acids during fasting (19).  In healthy 
humans it accounts for 30 to 45% of body weight.  In patients with neuromuscular 
disease, however, muscle mass may be reduced to 10% of body weight and increase the 
likelihood of hypoglycemic events during fasting or illness (10, 11). 
Body composition changes occur with progression of SMA and age.  As mobility 
decreases and metabolism slows, lean body mass becomes diminished, while an increase 
in fat mass occurs (5-8).  Changes in body composition may limit the ability of SMA 
patients to adjust to simple nutritional alterations especially during times of stress such as 
illness, fasting, or during surgery.  Given the continual advances in medical treatment for 
SMA patients, including surgical procedures benefiting and extending life, understanding 
tolerance for glucose loading and fasting would further serve to enhance their medical 
care.  Thus, the primary goals of this study were to: 1) generate patient blood chemistry 
values at dispersed time intervals before, during, and after periods of controlled fasting 
and 2) to assess glucose tolerance during an oral glucose tolerance test (OGTT).  It is 




disease such as type II diabetes in this population.  Therefore, body composition was 
measured to provide further insight into the metabolic risk factors of increased fat mass in 
the context of SMA disease progression.  Understanding potential glucose intolerances 






 Participants were recruited through a targeted campaign and collaboration with 
Families of SMA (FSMA).  Parents of current patients in the Pediatric Motor Disorders 
Research Program SMA database were contacted via email if they met eligibility criteria.  
Inclusion criteria consisted of a genetic diagnosis of SMA 5q and a clinical diagnosis of 
type II SMA, with the ability to sit, but not walk independently.  Exclusion criteria 
consisted of acute illness, use of a feeding tube for more than 50% of dietary 
requirements, inability to swallow safely, a medical diagnosis of diabetes (either type I or 
II), and daily use of an oral hypoglycemic agent or insulin therapy. 
 Consent was ensured by providing verbal and written explanation of the study, 
answering any questions or concerns, and obtaining signed parental consent.  Participant 
assent was obtained from all children as they were all ≥ 7 years old.  All participants 
travelled from out of state since local recruitment was unsuccessful.  The study was 
approved by the Institutional Review Board of the University of Utah #00064793.  Study 
funding was contributed by Families of SMA and supported by the National Center for 







 A clinical pilot study was conducted.  Children with SMA type II participated in 
an OGTT and a fasting challenge test at two separate visits 8 weeks apart.  Measurement 
outcomes included: metabolic laboratory measurements, anthropometric measures and 




 The study included two overnight visits at the University of Utah’s Center for 
Clinical and Translational Sciences (CCTS) located within the University of Utah 
Hospital.  Assessment of qualification and consent was obtained at the initial visit.  
Baseline measures included: DEXA analysis, anthropometric measures (weight, height, 
tricep skin fold (TSF), and mid-arm circumference (MAC)), as well as standard vital 
signs.  The subjects underwent an oral glucose tolerance test, during which they were 
given a glucose drink and then monitored for 3 hours.  Lab measures were taken at the 
beginning and throughout the test.  A fasting test was completed at the second visit at 
which time the subjects fasted until low blood glucose was achieved or until 20 hours 
passed; however, data related to this visit are not included in this study report. 
 
Oral Glucose Tolerance Test 
 
 Subjects were checked into the CCTS as inpatients, where consent was formally 
obtained by study staff.  Vital signs (blood pressure, % oxygen saturation, temperature, 




normal clothing, without shoes or additional gear.  If the subject was in a wheelchair, the 
weight of the chair was recorded or tared.  A Norland DEXA scan for small subjects 
(XR-36 software version 3.3.1, Fort Atkinson, Wisconsin) was performed on each subject 
as well as anthropometric measurements including:  height (recumbent length, arm span), 
tricep skin fold (TSF) using calipers (Lange Skinfold Caliper, Cambridge, Maryland), 
and mid-arm circumference (MAC) using a standard tape measure (cm).  Anthropometric 
measures were performed by the dietitian or trained study staff.  The subject was served a 
standardized meal and 100 ml of Pediasure was given as a final snack.  Regular 
medication was taken as needed.  Water or ice chips were given ad lib to ensure adequate 
hydration.  Any remainder of the standardized meal and snack was saved on the tray to be 
weighed and recorded by the dietitian the following morning.  Meal analysis was done 
using The Food Processor (version 9.1.0, and 10.5.2, 2003 and 2009 ESHA Research, 
Salem, Oregon) by the graduate nutrition student.  On average, approximately 400 
calories were consumed, consisting of 15% protein, 52% carbohydrate, and 33% fat.  The 
participants then fasted overnight for 8 hours.   
 Following the fast, urine was assessed for urinary ketones by study staff using 
KetoStix (Bayer HealthCare, Mishawaka, Indiana).  After the first void had been 
collected, the intravenous (IV) catheter was placed using a 20 or 22 gauge and was set up 
using a normal saline (NS) drip with double stop cock assembly.  Baseline samples were 
collected by a syringe.  Specifically, 6.5 ml of blood was pulled and transferred to 
collection tubes using a 21 gauge or larger transfer needle.  Baseline labs included 
analysis of hemoglobin A1c, insulin-like growth factor (IGF-1), blood glucose, insulin, 




glucose machine (YSI 2300 STAT PLUS, YSI Incorporated, Yellow Springs, Ohio) for 
safety purposes following the overnight fast. 
 Subjects consumed a glucose drink of 1.75 g glucose per kg body weight (not to 
exceed 75 g).  Blood samples were then collected at 30, 60, 90, 120, and 180 minutes.  
The samples were analyzed for blood glucose, insulin, glucagon, alanine, and cortisol.  At 
180 minutes, 0.5 ml blood was again collected for analysis by the YSI glucose machine 
for safety purposes.  Values less than <60 mg/dL required another glucose sample taken 
15 minutes after eating.  Urinary samples were collected and tested for ketones using 
KetoStix test strips throughout the 3 hours. 
 
Data Analysis 
 This study centered on recording time series changes in specific laboratory 
measurements within a rigorously selected sample of 6 SMA patients.  Blood glucose and 
other lab values collected during the OGTT were compared to established standards from 
ARUP Laboratories.  Anthropometric data were analyzed against Centers for Disease 
Control (CDC) standards and National Health and Nutrition Examination Survey 
(NHANES) data collected from 1999–2004.  This study is exploratory and descriptive in 
nature and the research data collected can be used to determine dietary protocols for the 






 Six subjects between the ages of 7 to 11 years were enrolled with an average age 
of 8.9 ± 1.7 years.  Preadolescents were selected to identify alterations in glucose 
metabolism prior to the dramatic growth and development during adolescence.  In 
addition, preadolescence is a common age group in this population for surgical 
procedures, especially for the treatment of scoliosis.  Four of the patients selected were 
male and 2 were female.  Five of the patients were Caucasian and 1 was Black Hispanic.  
One subject (A) had a feeding tube, which provided <50% of energy needs.  Participant 
characteristics and body composition are listed in Table 1.   
 Blood glucose values at the 120 minute interval indicated that 3 of the 6 patients 
showed glucose intolerance, with blood glucose values of 155, 169, and 185 mg/dL.  The 
average value for all subjects was 146.3 ± 27.6 mg/dL, which is considered to be just 
above the lower range for glucose intolerance based on the American Diabetes 
Association reference of 140 to 199 mg/dL (20).  A value greater than or equal to 200 
mg/dL is diagnostic for diabetes at the conclusion of an oral glucose tolerance test (20).  
Only the value from 1 subject (C) was close to that threshold with a reading of 185 
mg/dL.  When comparing the SMA type II patients to documented reference values (21), 
both groups’ blood glucose values peaked at the 30 minute mark on average.  Four of the 
SMA patients peaked at 30 minutes, while 1 peaked at 60 and 1 at 90 minutes.  Two of 




dropping at 60 minutes and increasing again at the 90 minute interval and remaining 
elevated to 120 minutes.  All 6 subjects were able to finish the glucose drink except 
subject (E) who drank all but 20 mL, consuming 1.55g/kg.  Subject (E) experienced 
hypoglycemia, which occurred at 180 minutes; blood glucose dropped to 53 mg/dL.  In 
summary, glucose values are shown in Figure 1 along with documented reference values. 
 Hemoglobin A1c labs collected at baseline were all within normal ranges for 5 of 
the 6 subjects.  Subject (B), however, had a value of 5.7%, which was above the normal 
ARUP reference range of 4.0-5.6%.  For this subject, the blood glucose value at the end 
of the OGTT was within the normal range at 127 mg/dL.  The 3 subjects with prediabetic 
blood glucose values included patients A, C, and D, all of whom had normal hemoglobin 
A1c values.   
 Insulin values were above referenced fasting values for 5 of the 6 subjects, which 
were greater than the ARUP reference value of 3-19 (μIU/mL).  Insulin values increased 
by over tenfold at the 30 minute interval, corresponding to the peak in glucose values at 
30 minutes.  The insulin values continued to climb with 4 out of the 6 subjects peaking in 
insulin levels at 120 minutes.  One subject peaked at 60 minutes, while another peaked at 
90.  All 3 of the subjects considered to have glucose intolerance values at the end of the 
OGTT (120 min interval) had their insulin values peak at this interval as well.  Normal 
ranges for 120 minutes are 22-79 μIU/mL.  All 6 of the patients’ insulin values far 
exceeded normal insulin ranges at the 2 hour mark with values from 244-929 μIU/mL.  
One subject (F), had the highest insulin value of 929 (μIU/mL) at 2 hours, but did not 




 All of the subjects had hyperinsulinemia based on the sum of insulin values 
collected throughout the OGTT (baseline, 30, 60, 90, and 120 minutes).  
Hyperinsulinemia is defined by an OGTT insulin sum of ≥300 (μIU/mL) (22, 23).  The 
range in total insulin values for all subjects was 1066-2641 (μIU/mL) and is illustrated in 
Figure 3.  
 Homeostasis model assessment for insulin resistance (HOMA-IR) is a validated 
equation for denoting insulin resistance based on the calculation of both fasting glucose 
and insulin values (23).  Four out of the 6 subjects had insulin resistance based on their 
HOMA-IR values.  Insulin resistance characteristics are outlined in Table 2.   
 Body fat composition and corresponding glucose intolerance/insulin resistance are 
outlined in Table 3.  Three out of the 6 subjects had glucose intolerance based on the 
results of the OGTT, with corresponding body fat percentages of 56.7, 76.1, and 82.1%.  
Subject B had the highest body fat percentage value of 83.4%, but did not have impaired  
glucose tolerance based on OGTT results. This subject did, however, have a HgbA1c of 
5.7%, a level considered prediabetic.  Two subjects (A, F) did not have insulin resistance 
based on HOMA-IR pubertal values and correspondingly had the lowest body fat 
percentages of the group (56.7 and 53.5%).  Subject A, despite a low body fat percentage 
(56.7%) and normal BMI of 15.6 kg/m², had impaired glucose tolerance with a value of 
169 mg/dL. 
For 3 out of the 6 subjects, alanine values peaked at baseline, whereas the other 3 
peaked at the 60, 90, and 120 minute intervals.  Meanwhile, for 5 out of the 6 subjects, 
alanine values were within the normal ARUP range of 150-570 μmol/L.  Only subject (C) 




peaked at baseline in 4 out of the 6 subjects and were above the reference value of 15 










Black Hispanic 1 
Age (years) 8.9 ± 1.7 
Height (cm) 131.8 ± 
13.8 
Weight (kg) 35.6 ± 8.3 
BMI (kg/m²) 20.5 ± 2.9 
Lean mass (kg) 10.4 ± 6.9 
Body fat (kg) 24.8 ± 4.7 
Body fat % 71.6 ± 13.1 




























A 99 14 3.42 ≥3.82 No 1069 
  
Yes 















E 87 29 6.23 ≥2.22¹ 
  
Yes 2120 Yes 
F 91 22 4.94 ≥5.22 No 2637 Yes 
HOMA-IR=Fasting insulin x Fasting 
glucose/405 
¹prepubertal ≤8-9 years 
HOMA-IR values based on pubertal status with prepubertal defined as ≤8-9 years (23). 
 





















A 15.6 16.4 Normal 56.7 5.3 169 3.42 
B 18.9 90.9 Overweight 83.4 5.7 127 7.89 
C 23.3 98.8 Obese 76.1 5.1 185 9.38 
D 21.3 97.5 Obese 82.1 4.9 155 3.78 
E 23.0 97.9 Obese 77.5 5.4 115 6.23 
F 20.8 86.1 Overweight 53.5 4.9 127 4.94 




Figure 1: Glucose Ranges 




Figure 2: Insulin Ranges 
Reference values from ARUP Labratories (maximum values plotted for insulin ranges 





Figure 3: Hyperinsulinemia 







 Our study discovered that 3 of the 6 enrolled subjects had glucose intolerance 
based on OGTT results.  In addition, 4 of the 6 had insulin resistance based on HOMA-IR 
data.  All 6 subjects had hyperinsulinemia, with total insulin sums exceeding 4 to 9 times 
that of the reference (≥300 (μIU/mL)).  Hemoglobin Alc values were only found to be 
prediabetic in 1 subject; however, the subject was not found to exhibit impaired glucose 
tolerance at the conclusion of the OGTT.  Considering that hemoglobin Alc values were 
within normal ranges for 5 of the 6 subjects, this test does not accurately detect glucose 
intolerance in SMA patients.  Five of the 6 subjects were overweight/obese based on BMI 
values.  Only 1 subject (A) fell within normal ranges on the CDC BMI chart with a BMI 
value of 15.6 kg/m².  However, DEXA revealed that all subjects had an average body fat 
percentage greater than 70%, which suggests all of the subjects were over fat. 
 No other research exists for oral glucose tolerance testing in humans with SMA.  
Mouse models of SMA and SMN depleted mice have shown the effects of testing mice 
with an intraperitoneal glucose tolerance test (IPGTT) (12, 13).  One mouse model tested 
SMA mice and found fasting hyperglycemia and hypergluconemia with diminished 
pancreatic β-cells.  However, in the most recent study, mice with reduced SMN protein 
(~50% of expected) were compared to wild type mice (WT) (13).  Findings revealed that 
despite no presence of neuromuscular disease, the SMN mice had glucose and pancreatic 




they had increased glucose levels during an IPGTT suggesting impaired glucose 
clearance.  The reduced ability to clear glucose was attributed to an increase in 
abnormally located α-cells within the pancreatic islet cores.  With age, the SMN mice 
gained more weight, had hyperinsulinemia, and increased hepatic glucagon sensitivity 
compared to the WT mice.  The SMN mice, despite not having a SMA phenotype, still 
had profound changes in glucose metabolism with pancreatic abnormalities.  In SMA 
human patients, disease severity is largely based on the SMN2 copy number; the more 
SMN2 copies present, the less severe form of disease.   
 The most recent Bowerman et al. study, although a mouse model, bridges the gap 
in understanding of the milder forms of SMA (types II, III, IV) and associated metabolic 
disease risk (13).  A connection between reduced SMN protein, regardless of SMA 
phenotype expression, and pancreatic/metabolic dysfunction exists.  Our study data 
highlight this unique metabolic dysfunction as well.  The reduction in SMN protein 
results in a slow progression of glucose abnormalities, as seen in our 6 study subjects.  
Developing a screening protocol for clinical application, such as timed glucose and 
insulin testing for glucose tolerance, is the first step needed to better understand glucose 
metabolism and suspected metabolism abnormalities in a larger SMA population.  An 
OGTT can provide these data and can be used as a way to screen patients and track 
metabolic changes. 
 All 6 of the study subjects were considered obese by National Health and 
Nutrition Examination Survey (NHANES) reference standards collected from 1999–2004 
(24).  Using DEXA scans, the NHANES data computed smoothed body fat percentages 






 percentile for boys (8 to 12.99 years) is 41.1 to 43.3%, while for girls it is 43.3 
to 44.4%.  Our subject DEXA scans reveal an average body fat percentage of 71.6% ± 
13.1 indicating that the SMA subjects far exceed the 95
th 
percentile for body fat.  BMI 
calculations also indicate that 5 of the 6 subjects were overweight or obese based on BMI 
percentiles.  Eighty three percent of the subjects were categorized as being overweight or 
obese (BMI ≥85th percentile) and 50% were considered obese (BMI ≥95th percentile). 
 Several studies have examined body composition for SMA patients and have 
found that body composition is not accurately depicted on a BMI growth chart (6, 9).  
Poruk et al. found that out of 47 type I SMA children, 68% of subjects plotted within the 




 percentiles on the BMI chart.  However, DEXA 
analysis revealed that the SMA children had substantially increased fat mass and lower 
fat free mass when compared to normal controls that plotted in the same BMI range. 
Sproule et al. reached a similar conclusion about body composition in SMA patients (9).  
Twenty-five children ages 5 to 18 years with SMA (2 type I, 13 type II, 10 type III) were 
assessed and compared to age-matched healthy children from NHANES data.  Despite 
the SMA patients falling within the normal ranges on the BMI curve, DEXA analysis 
indicated a higher percentage of fat mass with diminished lean body mass.  These higher 
percentages of fat mass placed them either in the “overweight” or “obese” categories.  























 All SMA subjects had reduced insulin sensitivity as indicated by the large total 
sum of insulin values and calculated HOMA-IR values.  A study by Kurtoğlu and 
colleagues studied insulin and glucose metabolism in 200 obese children and adolescents 
between the ages of 5 to 18 years (23).  Based on their OGTT, a calculation of fasting 
glucose and insulin values (HOMA-IR) was applied and cut off criteria for obese 
children/adolescents was generated. The study results indicated that differences in the 
rates of insulin resistance were based on pubertal status.  Those children in the 
prepubertal period, ≤8-9 years, had a rate of insulin resistance of 37% and 27.8% for boys 
and girls, respectively.  The pubertal period, in contrast, was marked by a higher 
percentage of insulin resistance; over 60% for both boys and girls.  They attributed this 
difference as a need for increased insulin resistance to aid in growth and development 
during puberty (23).  HOMA-IR values for insulin resistance were calculated to be ≥2.67 
and 2.22 for prepubertal boys and girls, while ≥5.22 and 3.82 was determined for pubertal 
boys and girls.  Five of the 6 SMA subjects in our study met the criterion for insulin 
resistance based on their HOMA-IR values corresponding to their age.  Interestingly, 
subject A, who had a glucose value of 169 mg/dL at the 120 minute interval during the 
OGTT, was not considered to have insulin resistance based on the HOMA-IR value.  Our 
study results are in contrast with the Korağlu et al. study as the SMA subjects had a much 
higher rate of insulin resistance.      
 Body composition, obesity, and dietary intake have significant impact on the 
development of glucose intolerance for all populations (20).  SMA subjects are at 
increased risk for developing obesity.  Only one published case of type II diabetes in a 




as disease progresses, glucose intolerance and insulin resistance develops.  Thus, it is 
imperative that dietary treatment be implemented to help control glucose and insulin 
values that were seen in our study.  Research indicates that based on OGTT results, 
fasting glucose, 120 minute glucose, fasting insulin, and 100 minute insulin are 
associated with the highest rates of mortality later in life (26).  In addition, a longitudinal 
study found a relationship between hyperinsulinemia preceding the development of type 
II diabetes 10 years earlier (27).  Three stages for the development of diabetes have been 
proposed.  The first stage includes hyperinsulinemia and normal to slightly elevated 
blood glucose.  The second stage includes insulin resistance and glucose intolerance, 
while stage three is the development of diabetes.  Many of the problems associated with 
the risk for cardiovascular disease (CVD) and metabolic syndrome occur during stages 
one and two, which occur 10 years prior to the development of diabetes (28).  Consuming 
a diet that is consistent in complex carbohydrate, balanced with adequate protein, fiber, 
and reduced fat, is recommended for managing the progression of metabolic disease.  In 
addition, awareness during times of illness and surgery, where dextrose may be 
administered for nutritional purposes should be considered.  Increased amounts of 
dextrose could spike glucose and insulin levels, leading to episodes of hyperglycemia and 
the potential for rebound hypoglycemia as seen at the conclusion of the OGTT with 
subject E.   
 To address changes in body composition, strategies to preserve muscle mass and 
mobility should be considered.  It is important that treatment for SMA patients involve 
working with an interdisciplinary team, which includes a physical therapist and dietitian.  




motion exercises, pool therapy, dance, and standing in a support stander for extended 
periods of time.  One subject (F) did conditioning and weight lifting exercise for upper 
body strength and to maintain lean muscle mass.  This subject had the lowest percentage 
of body fat out of the group at 53.5%. 
 
Strengths and Limitations 
 The strengths of this study include the diagnostic inclusion criteria and 
assessment methods.  The primary goal was to understand whether glucose abnormalities 
exist in children and adolescents with SMA type II who are otherwise healthy without 
any prior diagnosis of glucose intolerance or diabetes.  Furthermore, we took specific 
anthropometric measurements such as DEXA to further recognize the relationship 
between body composition and abnormalities with glucose regulation.  In addition, all of 
the specific plasma measures taken throughout the test were necessary in the diagnosis of 
metabolic abnormalities and glucose intolerance by providing first time laboratory data in 
a controlled hospital environment.  Overall, this study provides unique insight in a 
challenging population to recruit and study. 
 Limitations include the minimal number of participants, as sample size would not 
permit inferential statistical analysis.  However, findings have provided benchmarks for 
establishing dietary management of glucose metabolism abnormalities.  Although the 6 
SMA subjects did not have age-matched healthy peers for study comparison, inclusion 






Our research provides novel evidence that glucose metabolism abnormalities exist 
for overweight/obese SMA patients.  More research is needed on a larger scale to better 
understand the extent and potential treatments of such abnormalities.  Further 
understanding will influence the nutrition therapy provided during the course of medical 
care, which may help in the prevention of metabolic disease.   
 
  




Time Start Task Completed 
Y/N or record 
time 
2 pm Check into CCTS  
2:15-3:15 pm Consent obtained  
3:15 pm Vitals collected  
3:30 pm Anthropometrics collected  
3:30-4:00pm Clinical assessment  
4:00-5:00pm DEXA scan @ School of Medicine  
5 pm Standardized evening meal given  
8 pm Standardized evening snack given  
10 pm Overnight stay (8 hrs of fasting)  
6 am Collect baseline urinary ketone for first void  
6:15 am IV catheter placement, 20 or 22 gauge, with NS drip  
6:30 am Baseline blood lab collection: 
-(hemoglobin A1c, IGF-1, blood glucose, insulin, 
glucagon, alanine, cortisol). 
Collect 0.5 ml for glucose analysis by YSI.  Record glucose 







6:45 am Preparation of glucose drink (1.75g glucose/kg body 
weight not to exceed 75 g) 
 
7 am Glucose drink administered orally. 
Record time drink finished. 
 
--- Lab collection for: 
-(blood glucose, insulin, glucagon, alanine, cortisol) 
 
7:30 am 30 minutes  
8 am 60 minutes  
8:30 am 90 minutes  
9 am 120 minutes  
9:30 am 180 minutes  
 Collect 0.5 ml for glucose analysis by YSI. Record glucose 
level in “Lab Collection Checklist”. 
 
                
9:45 am Final urinary ketone collection  
10 am Conclusion of data collection  
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